Mechanisms of action of fluvoxamine for COVID-19: a historical review

DOI record: { "DOI": "10.1038/s41380-021-01432-3", "ISSN": [ "1359-4184", "1476-5578" ], "URL": "http://dx.doi.org/10.1038/s41380-021-01432-3", "alternative-id": [ "1432" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "4 October 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Revised", "name": "revised", "order": 2, "value": "13 December 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 3, "value": "23 December 2021" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 4, "value": "7 January 2022" }, { "group": { "label": "Conflict of interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "Dr. Y. Hashimoto and Dr. T. Suzuki have no conflict of interest. Dr. K. Hashimoto is the inventor of filed patent applications on “The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine and derivative thereof as a prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. K. Hashimoto has also received speakers’ honoraria, consultant fees, or research support from Abbott, Meiji Seika Pharma, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm, and Perception Neuroscience." }, { "label": "Free to read", "name": "free", "value": "This content has been made available to all." } ], "author": [ { "affiliation": [], "family": "Hashimoto", "given": "Yaeko", "sequence": "first" }, { "affiliation": [], "family": "Suzuki", "given": "Takuji", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-8892-0439", "affiliation": [], "authenticated-orcid": false, "family": "Hashimoto", "given": "Kenji", "sequence": "additional" } ], "container-title": [ "Molecular Psychiatry" ], "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2022, 1, 7 ] ], "date-time": "2022-01-07T10:02:49Z", "timestamp": 1641549769000 }, "deposited": { "date-parts": [ [ 2022, 1, 7 ] ], "date-time": "2022-01-07T11:06:11Z", "timestamp": 1641553571000 }, "indexed": { "date-parts": [ [ 2022, 1, 8 ] ], "date-time": "2022-01-08T05:51:27Z", "timestamp": 1641621087099 }, "is-referenced-by-count": 0, "issn-type": [ { "type": "print", "value": "1359-4184" }, { "type": "electronic", "value": "1476-5578" } ], "issued": { "date-parts": [ [ 2022, 1, 7 ] ] }, "language": "en", "license": [ { "URL": "https://www.springer.com/tdm", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 1, 7 ] ], "date-time": "2022-01-07T00:00:00Z", "timestamp": 1641513600000 } }, { "URL": "https://www.springer.com/tdm", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 1, 7 ] ], "date-time": "2022-01-07T00:00:00Z", "timestamp": 1641513600000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41380-021-01432-3.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41380-021-01432-3", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41380-021-01432-3.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2022, 1, 7 ] ] }, "published-online": { "date-parts": [ [ 2022, 1, 7 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1016/j.healun.2020.03.012", "author": "HK Siddiqi", "doi-asserted-by": "crossref", "first-page": "405", "journal-title": "J Heart Lung Transpl", "key": "1432_CR1", "unstructured": "Siddiqi HK, Mehra MR. COVID-19 illness in naïve and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transpl. 2020;39:405–7.", "volume": "39", "year": "2020" }, { "DOI": "10.1016/j.bbi.2020.03.031", "author": "Y Wu", "doi-asserted-by": "crossref", "first-page": "18", "journal-title": "Brain Behav Immun", "key": "1432_CR2", "unstructured": "Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22.", "volume": "87", "year": "2020" }, { "DOI": "10.1016/j.bbi.2020.03.007", "author": "Z Li", "doi-asserted-by": "crossref", "first-page": "916", "journal-title": "Brain Behav immun", "key": "1432_CR3", "unstructured": "Li Z, Ge J, Yang M, Feng J, Qiao M, Jiang R, et al. Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control. Brain Behav immun. 2020;88:916–9.", "volume": "88", "year": "2020" }, { "DOI": "10.1016/j.bbi.2020.05.075", "author": "J Zhang", "doi-asserted-by": "crossref", "first-page": "50", "journal-title": "Brain Behav Immun", "key": "1432_CR4", "unstructured": "Zhang J, Xu D, Xie B, Zhang Y, Huang H, Liu H, et al. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study. Brain Behav Immun. 2020;88:50–8.", "volume": "88", "year": "2020" }, { "DOI": "10.1038/s41380-021-01036-x", "author": "K Yuan", "doi-asserted-by": "crossref", "first-page": "4982", "journal-title": "Mol Psychiatry", "key": "1432_CR5", "unstructured": "Yuan K, Gong YM, Liu L, Sun YK, Tian SS, Wang YJ, et al. Prevalence of posttraumatic stress disorder after infectious disease pandemics in the twenty-first century, including COVID-19: a meta-analysis and systematic review. Mol Psychiatry. 2021;26:4982–98.", "volume": "26", "year": "2021" }, { "DOI": "10.3390/ijerph18168790", "author": "L Shi", "doi-asserted-by": "crossref", "first-page": "8790", "journal-title": "Int J Environ Res Public Health", "key": "1432_CR6", "unstructured": "Shi L, Lu ZA, Que JY, Huang XL, Lu QD, Liu L, et al. Long-term impact of COVID-19 on mental health among the general public: a nationwide longitudinal study in China. Int J Environ Res Public Health. 2021;18:8790.", "volume": "18", "year": "2021" }, { "DOI": "10.1007/s00406-020-01231-x", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "249", "journal-title": "Eur Arch psychiatry Clin Neurosci", "key": "1432_CR7", "unstructured": "Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch psychiatry Clin Neurosci. 2021;271:249–58.", "volume": "271", "year": "2021" }, { "DOI": "10.1002/minf.202000115", "author": "CN Cavasotto", "doi-asserted-by": "crossref", "first-page": "e2000115.", "journal-title": "Mol Inform", "key": "1432_CR8", "unstructured": "Cavasotto CN, Di Filippo JI. In silico drug repurposing for COVID-19: targeting SARS-CoV-2 proteins through docking and consensus ranking.Mol Inform. 2021;40:e2000115.", "volume": "40", "year": "2021" }, { "DOI": "10.1016/j.pharmthera.2021.107930", "author": "YL Ng", "doi-asserted-by": "crossref", "first-page": "107930", "journal-title": "Pharm Ther", "key": "1432_CR9", "unstructured": "Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: approaches, challenges and promising candidates. Pharm Ther. 2021;228:107930.", "volume": "228", "year": "2021" }, { "DOI": "10.1016/S2213-2600(21)00270-8", "author": "P Venkatesan", "doi-asserted-by": "crossref", "first-page": "e63", "journal-title": "Lancet Respir Med", "key": "1432_CR10", "unstructured": "Venkatesan P. Repurposing drugs for treatment of COVID-19. Lancet Respir Med. 2021;9:e63.", "volume": "9", "year": "2021" }, { "DOI": "10.1016/j.bbi.2020.04.046", "author": "J Zhang", "doi-asserted-by": "crossref", "first-page": "59", "journal-title": "Brain Behav Immun", "key": "1432_CR11", "unstructured": "Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun. 2020;87:59–73.", "volume": "87", "year": "2020" }, { "DOI": "10.1126/science.abi4708", "author": "TA Tummino", "doi-asserted-by": "crossref", "first-page": "541", "journal-title": "Science", "key": "1432_CR12", "unstructured": "Tummino TA, Rezelj VV, Fischer B, Fischer A, O’Meara MJ, Monel B, et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science. 2021;373:541–7.", "volume": "373", "year": "2021" }, { "DOI": "10.1016/j.metop.2021.100121", "author": "K Srivastava", "doi-asserted-by": "crossref", "first-page": "100121.", "journal-title": "Metab Open", "key": "1432_CR13", "unstructured": "Srivastava K, Singh MK. Drug repurposing in COVID-19: a review with past, present and future. Metab Open. 2021;12:100121.", "volume": "12", "year": "2021" }, { "DOI": "10.1001/jama.2020.22240", "author": "WH Self", "doi-asserted-by": "crossref", "first-page": "2165", "journal-title": "JAMA", "key": "1432_CR14", "unstructured": "Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:2165–76.", "volume": "324", "year": "2020" }, { "DOI": "10.1056/NEJMoa2021801", "author": "O Mitjà", "doi-asserted-by": "crossref", "first-page": "417", "journal-title": "N Eng J Med", "key": "1432_CR15", "unstructured": "Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Eng J Med. 2021;384:417–27.", "volume": "384", "year": "2021" }, { "DOI": "10.1001/jamanetworkopen.2021.6468", "author": "G Reis", "doi-asserted-by": "crossref", "first-page": "e216468", "journal-title": "JAMA Netw Open", "key": "1432_CR16", "unstructured": "Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. 2021;4:e216468.", "volume": "4", "year": "2021" }, { "DOI": "10.1001/jama.2021.3071", "author": "E López-Medina", "doi-asserted-by": "crossref", "first-page": "1426", "journal-title": "JAMA", "key": "1432_CR17", "unstructured": "López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021;325:1426–35.", "volume": "325", "year": "2021" }, { "DOI": "10.1007/s43440-021-00245-z", "author": "CS Kow", "doi-asserted-by": "crossref", "first-page": "1473", "journal-title": "Pharm Rep.", "key": "1432_CR18", "unstructured": "Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharm Rep. 2021;73:1473–9.", "volume": "73", "year": "2021" }, { "DOI": "10.1101/2021.05.21.21257595", "doi-asserted-by": "crossref", "key": "1432_CR19", "unstructured": "Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2021. ciab591." }, { "DOI": "10.1001/jama.2020.22760", "author": "E Lenze", "doi-asserted-by": "crossref", "first-page": "2292", "journal-title": "JAMA", "key": "1432_CR20", "unstructured": "Lenze E, Mattar C, Zorumski CF, Zorumski CF, Stevens A, Schweiger J, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. JAMA. 2020;324:2292–300.", "volume": "324", "year": "2020" }, { "DOI": "10.1038/s41380-021-01021-4", "author": "N Hoertel", "doi-asserted-by": "crossref", "first-page": "5199", "journal-title": "Mol Psychiatry", "key": "1432_CR21", "unstructured": "Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26:5199–212.", "volume": "26", "year": "2021" }, { "DOI": "10.1007/s00406-021-01326-z", "doi-asserted-by": "publisher", "key": "1432_CR22", "unstructured": "Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci. 2021. https://doi.org/10.1007/s00406-021-01326-z." }, { "DOI": "10.1093/ofid/ofab050", "author": "D Seftel", "doi-asserted-by": "crossref", "first-page": "ofab050", "journal-title": "Open Forum Infect Dis", "key": "1432_CR23", "unstructured": "Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8:ofab050.", "volume": "8", "year": "2021" }, { "DOI": "10.1016/S2214-109X(21)00448-4", "author": "G Reis", "doi-asserted-by": "publisher", "journal-title": "Lancet Glob Health", "key": "1432_CR24", "unstructured": "Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Milagres AC, Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized, platform clinical trial. Lancet Glob Health. 2021. https://doi.org/10.1016/S2214-109X(21)00448-4.", "year": "2021" }, { "key": "1432_CR25", "unstructured": "Sax PE. Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? NEJM J Watch. 2021. https://blogs.jwatch.org/hiv-id-observations/index.php/could-this-be-our-first-effective-inexpensive-widely-available-outpatient-treatEl-battrawy.Iment-for-covid-19/2021/08/12/." }, { "DOI": "10.1111/bcp.15126", "author": "M Calusic", "doi-asserted-by": "publisher", "journal-title": "Bri J Clin Pharm", "key": "1432_CR26", "unstructured": "Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Bri J Clin Pharm. 2021. https://doi.org/10.1111/bcp.15126.", "year": "2021" }, { "DOI": "10.1001/jamanetworkopen.2021.33090", "author": "T Oskotsky", "doi-asserted-by": "crossref", "first-page": "e2133090", "journal-title": "JAMA Netw Open", "key": "1432_CR27", "unstructured": "Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4:e2133090.", "volume": "4", "year": "2021" }, { "DOI": "10.23736/S0031-0808.21.04436-0.", "author": "L Fei", "doi-asserted-by": "publisher", "journal-title": "Panminerva Med", "key": "1432_CR28", "unstructured": "Fei L, Santarelli G, D’Anna G, Moretti S, Mirossi G, Patti A, et al. Can SSRI/SNRI antidepressants decrease the ‘cytokine storm’ in the course of COVID-19 pneumonia? Panminerva Med. 2021. https://doi.org/10.23736/S0031-0808.21.04436-0.", "year": "2021" }, { "DOI": "10.1016/S2215-0366(21)00232-7", "author": "B Vai", "doi-asserted-by": "crossref", "first-page": "797", "journal-title": "Lancet Psychiatry", "key": "1432_CR29", "unstructured": "Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental disorders and risk of COVID-19-related mortality, hospitalization, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021;8:797–812.", "volume": "8", "year": "2021" }, { "DOI": "10.1111/eci.13582", "author": "I El-Battrawy", "doi-asserted-by": "crossref", "first-page": "e13582.", "journal-title": "Eur J Clin Invest", "key": "1432_CR30", "unstructured": "El-Battrawy I, Nuñez-Gil IJ, Abumayyaleh M, Estrada V, Manuel Becerra-Muñoz V, Uribarri A, et al. COVID-19 and the impact of arterial hypertension- An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany). Eur J Clin Invest. 2021;51:e13582.", "volume": "51", "year": "2021" }, { "DOI": "10.1371/journal.pone.0247122", "author": "N Hoertel", "doi-asserted-by": "crossref", "first-page": "e0247122", "journal-title": "PLoS ONE", "key": "1432_CR31", "unstructured": "Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C, et al. Observational study of haloperidol in hospitalized patients with COVID-19. PLoS ONE. 2021;16:e0247122.", "volume": "16", "year": "2021" }, { "DOI": "10.1007/s40261-021-01001-0", "author": "N Hoertel", "doi-asserted-by": "crossref", "first-page": "221", "journal-title": "Clin Drug Invest", "key": "1432_CR32", "unstructured": "Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C, et al. Observational study of chlorpromazine in hospitalized patients with COVID-19. Clin Drug Invest. 2021;41:221–33.", "volume": "41", "year": "2021" }, { "DOI": "10.1073/pnas.81.17.5618", "author": "SW Tam", "doi-asserted-by": "crossref", "first-page": "5618", "journal-title": "Proc Natl Acad Sci USA", "key": "1432_CR33", "unstructured": "Tam SW, Cook L. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]SKF10,047 and [3H]haloperidol binding in guinea pig brain membranes. Proc Natl Acad Sci USA. 1984;81:5618–21.", "volume": "81", "year": "1984" }, { "DOI": "10.1016/0014-2999(90)90356-B", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "295", "journal-title": "Eur J Pharm", "key": "1432_CR34", "unstructured": "Hashimoto K, Goromaru T. High-affinity binding of [3H]6-nitroquipazine to 5-hydroxytryptamine transporter in human platelets. Eur J Pharm. 1990;187:295–302.", "volume": "187", "year": "1990" }, { "DOI": "10.1160/TH03-05-0330", "author": "E Maurer-Spurej", "doi-asserted-by": "crossref", "first-page": "119", "journal-title": "Thromb Haemost", "key": "1432_CR35", "unstructured": "Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119–28.", "volume": "91", "year": "2004" }, { "DOI": "10.1182/blood-2011-09-336933", "author": "G Jedlitschky", "doi-asserted-by": "crossref", "first-page": "3394", "journal-title": "Blood", "key": "1432_CR36", "unstructured": "Jedlitschky G, Greinacher A, Kroemer HK. Transporters in human platelets: physiologic function and impact for pharmacotherapy. Blood. 2012;119:3394–402.", "volume": "119", "year": "2012" }, { "DOI": "10.3389/fphar.2021.652688", "author": "VP Sukhatme", "doi-asserted-by": "crossref", "first-page": "652688", "journal-title": "Front Pharm", "key": "1432_CR37", "unstructured": "Sukhatme VP, Reiersen AM, Vayttaden SJ, Sykhatme W. Fluvoxamine: a review of its mechanisms of actions and its role in COVID-19. Front Pharm. 2021;12:652688.", "volume": "12", "year": "2021" }, { "DOI": "10.1016/j.bbi.2011.12.011", "author": "RJ Tynan", "doi-asserted-by": "crossref", "first-page": "469", "journal-title": "Brain Behav Immun", "key": "1432_CR38", "unstructured": "Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walter FR. A comparative examination of the antiinflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26:469–79.", "volume": "26", "year": "2012" }, { "DOI": "10.1016/j.pbb.2012.12.003", "author": "Y Ohgi", "doi-asserted-by": "crossref", "first-page": "853", "journal-title": "Pharm Biochem Behav", "key": "1432_CR39", "unstructured": "Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants on alterations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharm Biochem Behav. 2013;103:853–9.", "volume": "103", "year": "2013" }, { "DOI": "10.1016/j.pbb.2016.02.005", "author": "C Dong", "doi-asserted-by": "crossref", "first-page": "7", "journal-title": "Pharm Biochem Behav", "key": "1432_CR40", "unstructured": "Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, et al. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-alpha, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharm Biochem Behav. 2016;144:7–12.", "volume": "144", "year": "2016" }, { "DOI": "10.3390/ijms16047796", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "7796", "journal-title": "Int J Mol Sci", "key": "1432_CR41", "unstructured": "Hashimoto K. Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci. 2015;16:7796–801.", "volume": "16", "year": "2015" }, { "DOI": "10.1016/j.bbi.2019.02.021", "author": "L Wang", "doi-asserted-by": "crossref", "first-page": "24", "journal-title": "Brain Behav Immun", "key": "1432_CR42", "unstructured": "Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain Behav Immun. 2019;79:24–38.", "volume": "79", "year": "2019" }, { "DOI": "10.1016/j.bbr.2016.08.005", "author": "E Dallé", "doi-asserted-by": "crossref", "first-page": "189", "journal-title": "Behav Brain Res", "key": "1432_CR43", "unstructured": "Dallé E, Daniels WM, Mabandia MV. Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression. Behav Brain Res. 2017;316:189–96.", "volume": "316", "year": "2017" }, { "author": "L Rafiee", "first-page": "977", "journal-title": "Iran J Basic Med Sci", "key": "1432_CR44", "unstructured": "Rafiee L, Hajhashemi V, Javanmard SH. Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic Med Sci. 2016;19:977–84.", "volume": "19", "year": "2016" }, { "DOI": "10.1038/s41598-017-04968-z", "author": "M Ghareghani", "doi-asserted-by": "crossref", "journal-title": "Sci Rep.", "key": "1432_CR45", "unstructured": "Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, et al. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci Rep. 2017;7:4923.", "volume": "7", "year": "2017" }, { "DOI": "10.1016/0006-2952(91)90169-6", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "1679", "journal-title": "Biochem Pharm", "key": "1432_CR46", "unstructured": "Hashimoto K, Goromaru T. High-affinity [3H]6-nitroquipazine binding to the 5-hydroxytryptamine transport system in rat lung. Biochem Pharm. 1991;41:1679–82.", "volume": "41", "year": "1991" }, { "DOI": "10.1016/0883-2897(87)90030-4", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "587", "journal-title": "Int J Rad Appl Instrum B", "key": "1432_CR47", "unstructured": "Hashimoto K, Inoue O, Suzuki K, Yamasaki T, Kojima M. Synthesis and evaluation of [11C]cyanoimipramine. Int J Rad Appl Instrum B. 1987;46:587–92.", "volume": "46", "year": "1987" }, { "DOI": "10.1007/s00259-002-0884-4", "author": "A Takano", "doi-asserted-by": "crossref", "first-page": "1289", "journal-title": "Eur J Nucl Med", "key": "1432_CR48", "unstructured": "Takano A, Suhara T, Sudo Y, Inoue M, Hashimoto K, Zhang MR, et al. Comparative evaluation of two serotonin transporter ligands in the human brain: [11C](+)McN5652 and [11C]cyanoimipramine. Eur J Nucl Med. 2002;29:1289–97.", "volume": "29", "year": "2002" }, { "DOI": "10.1007/978-3-662-45805-1_15", "author": "S Adnot", "doi-asserted-by": "crossref", "first-page": "365", "journal-title": "Handb Exp Pharm", "key": "1432_CR49", "unstructured": "Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin transporter and serotonin receptors. Handb Exp Pharm. 2013;218:365–80.", "volume": "218", "year": "2013" }, { "DOI": "10.1016/j.euroneuro.2021.09.009", "author": "MG Mazza", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Eur Neuropsychopharmacol", "key": "1432_CR50", "unstructured": "Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol. 2021;54:1–6.", "volume": "54", "year": "2021" }, { "DOI": "10.1128/JVI.03557-12", "author": "M Friesland", "doi-asserted-by": "crossref", "first-page": "6377", "journal-title": "J Virol", "key": "1432_CR51", "unstructured": "Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 receptor regulates early steps of viral RNA replication at the inset of hepatitis C virus infection. J Virol. 2013;87:6377–90.", "volume": "87", "year": "2013" }, { "DOI": "10.1016/j.virusres.2015.03.013", "author": "C Vasallo", "doi-asserted-by": "crossref", "first-page": "100", "journal-title": "Virus Res", "key": "1432_CR52", "unstructured": "Vasallo C, Gastaminza P. Cellular stress response in hepatitis C virus infection: mastering a two-edged sword. Virus Res. 2015;209:100–17.", "volume": "209", "year": "2015" }, { "DOI": "10.1038/s41586-020-2286-9", "author": "DE Gordon", "doi-asserted-by": "crossref", "first-page": "459", "journal-title": "Nature", "key": "1432_CR53", "unstructured": "Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–68.", "volume": "583", "year": "2020" }, { "DOI": "10.1126/science.abe9403", "author": "DE Gordon", "doi-asserted-by": "crossref", "first-page": "eabe9403.", "journal-title": "Science", "key": "1432_CR54", "unstructured": "Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020;370:eabe9403.", "volume": "370", "year": "2020" }, { "DOI": "10.3389/fphar.2020.582310", "author": "JM Vela", "doi-asserted-by": "crossref", "first-page": "582310", "journal-title": "Front Pharm", "key": "1432_CR55", "unstructured": "Vela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy? Front Pharm. 2020;11:582310.", "volume": "11", "year": "2020" }, { "DOI": "10.1080/14728222.2021.1952987", "author": "JM Brimson", "doi-asserted-by": "crossref", "first-page": "435", "journal-title": "Expert Opin Ther Targets", "key": "1432_CR56", "unstructured": "Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, Tencomnao T. Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the sigma-1 receptor and autophagy. Expert Opin Ther Targets. 2021;25:435–49.", "volume": "25", "year": "2021" }, { "DOI": "10.1016/0014-2999(96)00254-3", "author": "N Narita", "doi-asserted-by": "crossref", "first-page": "117", "journal-title": "Eur J Pharm", "key": "1432_CR57", "unstructured": "Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interaction of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharm. 1996;307:117–9.", "volume": "307", "year": "1996" }, { "DOI": "10.1073/pnas.93.15.8072", "author": "M Hanner", "doi-asserted-by": "crossref", "first-page": "8072", "journal-title": "Proc Natl Acad Sci USA", "key": "1432_CR58", "unstructured": "Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA. 1996;93:8072–7.", "volume": "93", "year": "1996" }, { "DOI": "10.1016/j.cell.2007.08.036", "author": "T Hayashi", "doi-asserted-by": "crossref", "first-page": "596", "journal-title": "Cell", "key": "1432_CR59", "unstructured": "Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell. 2007;131:596–610.", "volume": "131", "year": "2007" }, { "DOI": "10.1517/14728222.2011.560837", "author": "T Hayashi", "doi-asserted-by": "crossref", "first-page": "557", "journal-title": "Expert Opin Ther Targets", "key": "1432_CR60", "unstructured": "Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets. 2011;15:557–77.", "volume": "15", "year": "2011" }, { "DOI": "10.1124/jpet.102.041970", "author": "M Takebayashi", "doi-asserted-by": "crossref", "first-page": "1227", "journal-title": "J Pharm Exp Ther", "key": "1432_CR61", "unstructured": "Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharm Exp Ther. 2002;303:1227–37.", "volume": "303", "year": "2002" }, { "DOI": "10.1371/journal.pone.0002558", "author": "T Nishimura", "doi-asserted-by": "crossref", "first-page": "e2558", "journal-title": "PLoS ONE", "key": "1432_CR62", "unstructured": "Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. 2008;3:e2558.", "volume": "3", "year": "2008" }, { "DOI": "10.1016/j.ejphar.2014.01.064", "author": "T Ishima", "doi-asserted-by": "crossref", "first-page": "167", "journal-title": "Eur J Pharm", "key": "1432_CR63", "unstructured": "Ishima T, Fujita Y, Hashimoto K. Interactions of new antidepressants with sigma-1 receptor chaperons and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharm. 2014;727:167–73.", "volume": "727", "year": "2014" }, { "DOI": "10.1016/j.biopsych.2007.04.001", "author": "M Ishikawa", "doi-asserted-by": "crossref", "first-page": "878", "journal-title": "Biol Psychiatry", "key": "1432_CR64", "unstructured": "Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography using [11C]SA4503. Biol Psychiatry. 2007;62:878–83.", "volume": "62", "year": "2007" }, { "DOI": "10.1002/hup.1106", "author": "I Hindmarch", "doi-asserted-by": "crossref", "first-page": "193", "journal-title": "Hum Psychopharmacol", "key": "1432_CR65", "unstructured": "Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;25:193–200.", "volume": "25", "year": "2010" }, { "DOI": "10.2174/138161212799436476", "author": "T Niitsu", "doi-asserted-by": "crossref", "first-page": "875", "journal-title": "Curr Pharm Des", "key": "1432_CR66", "unstructured": "Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric disorders. Curr Pharm Des. 2012;18:875–83.", "volume": "18", "year": "2012" }, { "DOI": "10.1016/j.jphs.2014.11.010", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "6", "journal-title": "J Pharm Sci", "key": "1432_CR67", "unstructured": "Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication. J Pharm Sci. 2015;127:6–9.", "volume": "127", "year": "2015" }, { "DOI": "10.1007/978-3-319-50174-1_11", "author": "Y Albayrak", "doi-asserted-by": "crossref", "first-page": "153", "journal-title": "Adv Exp Med Biol", "key": "1432_CR68", "unstructured": "Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical implication in neuropsychiatric disorders. Adv Exp Med Biol. 2017;964:153–61.", "volume": "964", "year": "2017" }, { "DOI": "10.1126/scitranslmed.aau5266", "author": "DA Rosen", "doi-asserted-by": "crossref", "first-page": "eaau5266.", "journal-title": "Sci Transl Med", "key": "1432_CR69", "unstructured": "Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11:eaau5266.", "volume": "11", "year": "2019" }, { "DOI": "10.1016/j.pneurobio.2012.09.001", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "15", "journal-title": "Prog Neurobiol", "key": "1432_CR70", "unstructured": "Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15–29.", "volume": "100", "year": "2013" }, { "DOI": "10.3389/fpubh.2020.00152", "author": "JM Jin", "doi-asserted-by": "crossref", "first-page": "152", "journal-title": "Front Public Health", "key": "1432_CR71", "unstructured": "Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health. 2020;8:152.", "volume": "8", "year": "2020" }, { "DOI": "10.1186/s13293-020-00304-9", "author": "C Gebhard", "doi-asserted-by": "crossref", "first-page": "29.", "journal-title": "Biol Sex Differ", "key": "1432_CR72", "unstructured": "Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:29.", "volume": "11", "year": "2020" }, { "DOI": "10.1111/andr.12993", "author": "A Salonia", "doi-asserted-by": "crossref", "first-page": "1043", "journal-title": "Andrology", "key": "1432_CR73", "unstructured": "Salonia A, Pontillo M, Capogrosso P, Gregori S, Tassara M, Boeri L, et al. Severely low testosterone in males with COVID-19: a case-control study. Andrology. 2021;9:1043–52.", "volume": "9", "year": "2021" }, { "DOI": "10.1001/jamanetworkopen.2021.11398", "author": "S Dhindsa", "doi-asserted-by": "crossref", "first-page": "e2111398", "journal-title": "JAMA Netw Open", "key": "1432_CR74", "unstructured": "Dhindsa S, Zhang N, McPhaul MJ, Wu Z, Ghoshal AK, Erlich EC, et al. Association of circulating sex hormones with inflammation and disease severity in patients with COVID-19. JAMA Netw Open. 2021;4:e2111398.", "volume": "4", "year": "2021" }, { "DOI": "10.3389/fendo.2021.694083", "author": "L Lanser", "doi-asserted-by": "crossref", "first-page": "694083.", "journal-title": "Front Endocrinol (Lausanne)", "key": "1432_CR75", "unstructured": "Lanser L, Burkert FR, Thommens L, Egger A, Hoermann G, Kaser S, et al. Testosterone deficiency is a risk factor for severe COVID-19. Front Endocrinol (Lausanne). 2021;12:694083.", "volume": "12", "year": "2021" }, { "DOI": "10.1016/j.endmts.2021.100110", "author": "SB Shah", "doi-asserted-by": "crossref", "first-page": "100110", "journal-title": "Endcr Metab Sci", "key": "1432_CR76", "unstructured": "Shah SB. COVID-19 and progesterone: Part 1. SARS-CoV-2, progesterone and its potential clinical use. Endcr Metab Sci. 2021;5:100110.", "volume": "5", "year": "2021" }, { "DOI": "10.1016/j.endmts.2021.100110", "author": "SB Shah", "doi-asserted-by": "crossref", "first-page": "100110", "journal-title": "Endcr Metab Sci", "key": "1432_CR77", "unstructured": "Shah SB. COVID-19 and progesterone: Part 2. Unraveling high severity, immunity patterns, immunity grading, progesterone and its potential clinical use. Endcr Metab Sci. 2021;5:100110.", "volume": "5", "year": "2021" }, { "DOI": "10.1016/j.chest.2021.02.024", "author": "S Ghandehari", "doi-asserted-by": "crossref", "first-page": "74", "journal-title": "Chest", "key": "1432_CR78", "unstructured": "Ghandehari S, Matusov Y, Pepkowitz S, Stein D, Kaderi T, Narayanan D, et al. Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial. Chest. 2021;160:74–84.", "volume": "160", "year": "2021" }, { "DOI": "10.1038/sj.npp.1301047", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "514", "journal-title": "Neuropsychopharmacology", "key": "1432_CR79", "unstructured": "Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. 2007;32:514–21.", "volume": "32", "year": "2007" }, { "DOI": "10.33594/000000021", "author": "C Li", "doi-asserted-by": "crossref", "first-page": "280", "journal-title": "Cell Physiol Biochem", "key": "1432_CR80", "unstructured": "Li C, Wang A, Wu Y, Gulbins E, Grassmé H, Zhao Z. Acid sphingomyelinase-ceramide system in bacterial infections. Cell Physiol Biochem. 2019;52:280–301.", "volume": "52", "year": "2019" }, { "DOI": "10.3390/ijms22115676", "author": "N Beckmann", "doi-asserted-by": "crossref", "first-page": "5676", "journal-title": "Int J Mol Sci", "key": "1432_CR81", "unstructured": "Beckmann N, Becker KA. Ceramide and related molecules in viral infections. Int J Mol Sci. 2021;22:5676.", "volume": "22", "year": "2021" }, { "DOI": "10.3389/fcell.2021.689854", "author": "K Törnquist", "doi-asserted-by": "crossref", "first-page": "689854.", "journal-title": "Front Cell Dev Biol", "key": "1432_CR82", "unstructured": "Törnquist K, Asghar MY, Srinivasan V, Korhonen L, Lindholm D. Sphingolipids as modulators of SARS-CoV-2 infection. Front Cell Dev Biol. 2021;9:689854.", "volume": "9", "year": "2021" }, { "DOI": "10.1038/s41380-021-01309-5", "doi-asserted-by": "publisher", "key": "1432_CR83", "unstructured": "Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01309-5." }, { "DOI": "10.1159/000315101", "author": "J Kornhuber", "doi-asserted-by": "crossref", "first-page": "9", "journal-title": "Cell Physiol Biochem", "key": "1432_CR84", "unstructured": "Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, et al. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26:9–20.", "volume": "26", "year": "2010" }, { "DOI": "10.1038/nm.3214", "author": "E Gulbins", "doi-asserted-by": "crossref", "first-page": "934", "journal-title": "Nat Med", "key": "1432_CR85", "unstructured": "Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, et al. Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med. 2013;19:934–8.", "volume": "19", "year": "2013" }, { "DOI": "10.1038/s41380-018-0090-9", "author": "A Gulbins", "doi-asserted-by": "crossref", "first-page": "2324", "journal-title": "Mol Psychiatry", "key": "1432_CR86", "unstructured": "Gulbins A, Schumacher F, Becker KA, Wilker B, Soddemann M, Boldrin F, et al. Antidepressants act by inducing autophagy controlled by sphingomyelin-ceramide. Mol Psychiatry. 2018;23:2324–46.", "volume": "23", "year": "2018" }, { "DOI": "10.1016/j.xcrm.2020.100142", "author": "A Carpinteiro", "doi-asserted-by": "crossref", "first-page": "100142", "journal-title": "Cell Rep Med", "key": "1432_CR87", "unstructured": "Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1:100142.", "volume": "1", "year": "2020" }, { "DOI": "10.3390/ph14070691", "author": "G Loas", "doi-asserted-by": "crossref", "first-page": "691.", "journal-title": "Pharm (Basel)", "key": "1432_CR88", "unstructured": "Loas G, Le Corre P. Update on functional inhibitors of acid sphingomyelinase (FISMAs) in SARS-CoV-2 infection. Pharm (Basel). 2021;14:691.", "volume": "14", "year": "2021" }, { "DOI": "10.1371/journal.pone.0023852", "author": "J Kornhuber", "doi-asserted-by": "crossref", "first-page": "e23852", "journal-title": "PLoS ONE", "key": "1432_CR89", "unstructured": "Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS ONE. 2011;6:e23852.", "volume": "6", "year": "2011" }, { "DOI": "10.1002/cpt.2317", "author": "N Hoertel", "doi-asserted-by": "crossref", "first-page": "1498", "journal-title": "Clin Pharm Ther", "key": "1432_CR90", "unstructured": "Hoertel N, Sánchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze EJ, et al. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study. Clin Pharm Ther. 2021;110:1498–511.", "volume": "110", "year": "2021" }, { "DOI": "10.1016/j.ijantimicag.2020.106274", "author": "M Plaze", "doi-asserted-by": "crossref", "first-page": "106274", "journal-title": "Int J Antimicrob Agents", "key": "1432_CR91", "unstructured": "Plaze M, Attali D, Prot M, Petit AC, Blatzer M, Vinckier F, et al. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine. Int J Antimicrob Agents. 2021;57:106274.", "volume": "57", "year": "2021" }, { "DOI": "10.1038/s41380-021-01254-3", "doi-asserted-by": "publisher", "key": "1432_CR92", "unstructured": "Hoertel N, Sánchez-Rico M, Cougoule C, Gulbins E, Kornhuber J, Carpinteiro A, et al. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01254-3." }, { "DOI": "10.1016/j.lfs.2020.117583", "author": "R Zhang", "doi-asserted-by": "crossref", "first-page": "117583.", "journal-title": "Life Sci", "key": "1432_CR93", "unstructured": "Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjunct treatment. Life Sci. 2020;250:117583.", "volume": "250", "year": "2020" }, { "DOI": "10.1002/rmv.2109", "author": "G Anderson", "doi-asserted-by": "crossref", "first-page": "e2109.", "journal-title": "Rev Med Virol", "key": "1432_CR94", "unstructured": "Anderson G, Reiter RJ. Melatonin: roles in influenza, Covid-19, and other infections. Rev Med Virol. 2020;30:e2109.", "volume": "30", "year": "2020" }, { "DOI": "10.1007/s00213-020-05753-z", "author": "GM Anderson", "doi-asserted-by": "crossref", "first-page": "611", "journal-title": "Psychopharmacology", "key": "1432_CR95", "unstructured": "Anderson GM. Fluvoxamine, melatonin and COVID-19. Psychopharmacology. 2021;238:611.", "volume": "238", "year": "2021" }, { "DOI": "10.1080/14787210.2017.1305888", "author": "C Salata", "doi-asserted-by": "crossref", "first-page": "483", "journal-title": "Expert Rev Anti Infect Ther", "key": "1432_CR96", "unstructured": "Salata C, Calistri A, Parolin C, Baritussio A, Palù G. Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther. 2017;15:483–92.", "volume": "15", "year": "2017" }, { "DOI": "10.3389/fphar.2021.787261", "author": "OO Glebov", "doi-asserted-by": "crossref", "first-page": "787261", "journal-title": "Front Pharmacol", "key": "1432_CR97", "unstructured": "Glebov OO. Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants. Front Pharmacol. 2021;21:787261.", "volume": "21", "year": "2021" }, { "DOI": "10.1101/2021.03.22.436379", "doi-asserted-by": "crossref", "key": "1432_CR98", "unstructured": "Fred SM, Kuivanen S, Ugurlu H, Casarotto PC, Levanov L, Saksela K, et al. Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro. bioRxiv 10.110/2021.03.22.436379 [Preprint]." }, { "DOI": "10.1093/schbul/sbq146", "author": "AS Brown", "doi-asserted-by": "crossref", "first-page": "284", "journal-title": "Schizophr Bull", "key": "1432_CR99", "unstructured": "Brown AS, Patterson PH. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull. 2011;37:284–90.", "volume": "37", "year": "2011" }, { "DOI": "10.1016/j.molmed.2011.03.001", "author": "PH Patterson", "doi-asserted-by": "crossref", "first-page": "389", "journal-title": "Trends Mol Med", "key": "1432_CR100", "unstructured": "Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med. 2011;17:389–94.", "volume": "17", "year": "2011" }, { "DOI": "10.1176/appi.ajp.2018.17121311", "author": "AS Brown", "doi-asserted-by": "crossref", "first-page": "1073", "journal-title": "Am J Psychiatry", "key": "1432_CR101", "unstructured": "Brown AS, Meyer U. Maternal immune activation and neuropsychiatric illness: a translational research perspective. Am J Psychiatry. 2018;175:1073–83.", "volume": "175", "year": "2018" }, { "DOI": "10.1001/archpsyc.61.8.774", "author": "AS Brown", "doi-asserted-by": "crossref", "first-page": "774", "journal-title": "Arch Gen Psychiatry", "key": "1432_CR102", "unstructured": "Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. 2004;61:774–80.", "volume": "61", "year": "2004" }, { "DOI": "10.1007/s10803-010-1006-y", "author": "HO Atladóttir", "doi-asserted-by": "crossref", "first-page": "1423", "journal-title": "J Autism Dev Disord", "key": "1432_CR103", "unstructured": "Atladóttir HO, Thorsen P, Østergaard L, Schendel DE, Lemcke S, Abdallah M, et al. maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J Autism Dev Disord. 2010;40:1423–30.", "volume": "40", "year": "2010" }, { "DOI": "10.3389/fmed.2020.573468", "author": "MM Islam", "doi-asserted-by": "crossref", "first-page": "573468", "journal-title": "Front Med", "key": "1432_CR104", "unstructured": "Islam MM, Poly TN, Walther BA, Yang HC, Wang CW, Hsieh WS, et al. Clinical characteristics and neonatal outcomes of pregnant patients with COVID-19: a systematic review. Front Med. 2020;7:573468.", "volume": "7", "year": "2020" }, { "DOI": "10.1016/j.cyto.2021.155431", "author": "A Tanacan", "doi-asserted-by": "crossref", "first-page": "155431", "journal-title": "Cytokine", "key": "1432_CR105", "unstructured": "Tanacan A, Yazihan N, Erol SA, Anuk AT, Yetiskin FDY, Burken D, et al. The impact of COVID-19 infection on the cytokine profile of pregnant women: a prospective case-control study. Cytokine. 2021;140:155431.", "volume": "140", "year": "2021" }, { "DOI": "10.1007/978-3-030-59261-5_27", "author": "S Makvandi", "doi-asserted-by": "crossref", "first-page": "299", "journal-title": "Adv Exp Med Biol", "key": "1432_CR106", "unstructured": "Makvandi S, Mahdavian M, Kazemi-Nia G, Vahedian-Azimi A, Guest PC, Karimi L, et al. The 2019 novel coronavirus disease in pregnancy: a systematic review. Adv Exp Med Biol. 2021;1321:299–307.", "volume": "1321", "year": "2021" }, { "DOI": "10.1371/journal.pone.0253974", "author": "A Ciapponi", "doi-asserted-by": "crossref", "first-page": "e0253974.", "journal-title": "PLoS ONE", "key": "1432_CR107", "unstructured": "Ciapponi A, Bardach A, Comandé D, Berrueda M, Argento FJ, Cairoli FR, et al. COVID-19 and pregnancy: an umbrella review of clinical presentation, vertical transmission, and maternal and perinatal outcomes. PLoS ONE. 2021;16:e0253974.", "volume": "16", "year": "2021" }, { "DOI": "10.1001/jamapediatrics.2021.1050", "author": "J Villar", "doi-asserted-by": "crossref", "first-page": "817", "journal-title": "JAMA Pediatr", "key": "1432_CR108", "unstructured": "Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175:817–26.", "volume": "175", "year": "2021" }, { "DOI": "10.1056/NEJMoa2104983", "author": "TT Shimabukuro", "doi-asserted-by": "crossref", "first-page": "2273", "journal-title": "N. Eng J Med", "key": "1432_CR109", "unstructured": "Shimabukuro TT, Kim SY, Meyers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N. Eng J Med. 2021;384:2273–82.", "volume": "384", "year": "2021" }, { "author": "A Matsuura", "journal-title": "Sci Rep.", "key": "1432_CR110", "unstructured": "Matsuura A, Ishima T, Fujita Y, Iwayama Y, Hasegawa S, Kawahara-Miki R, et al. Dietary glucoraphanin prevents the onset of psychosis in the adult offspring after maternal immune activation. Sci Rep. 2018;8:2158.", "volume": "8", "year": "2018" }, { "DOI": "10.1002/npr2.12112", "author": "Y Fujita", "doi-asserted-by": "crossref", "first-page": "268", "journal-title": "Neuropsychopharmacol Rep.", "key": "1432_CR111", "unstructured": "Fujita Y, Fujita A, Ishima T, Hirai A, Suzuki S, Suganuma H, et al. Dietary intake of glucoraphanin during pregnancy and lactation prevents the behavioral abnormalities in the offspring after maternal immune activation. Neuropsychopharmacol Rep. 2020;40:268–74.", "volume": "40", "year": "2020" }, { "DOI": "10.1007/s11920-019-1063-7", "author": "K Hashimoto", "doi-asserted-by": "crossref", "journal-title": "Curr Psychiatry Rep.", "key": "1432_CR112", "unstructured": "Hashimoto K. Recent advances in the early intervention in schizophrenia: future direction from preclinical findings. Curr Psychiatry Rep. 2019;21:75.", "volume": "21", "year": "2019" }, { "DOI": "10.1007/s00406-020-01148-5", "author": "K Hashimoto", "doi-asserted-by": "crossref", "first-page": "387", "journal-title": "Eur Arch Psychiatry Clin Neurosci", "key": "1432_CR113", "unstructured": "Hashimoto K. Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention. Eur Arch Psychiatry Clin Neurosci. 2021;271:387–9.", "volume": "271", "year": "2021" }, { "DOI": "10.1002/ped4.12199", "author": "Y Li", "doi-asserted-by": "crossref", "first-page": "118", "journal-title": "Pediatr Investig", "key": "1432_CR114", "unstructured": "Li Y, Freedman R. Prospects for improving future mental health of children through prenatal maternal micronutrient supplementation in China. Pediatr Investig. 2020;4:118–26.", "volume": "4", "year": "2020" }, { "DOI": "10.1016/j.bbih.2021.100297", "author": "B Lins", "doi-asserted-by": "crossref", "first-page": "100297.", "journal-title": "Brain Behav Immun Health", "key": "1432_CR115", "unstructured": "Lins B. Maternal immune activation as a risk factor for psychiatric illness in the context of the SARS-CoV-2 pandemic. Brain Behav Immun Health. 2021;16:100297.", "volume": "16", "year": "2021" }, { "DOI": "10.1016/j.clnesp.2021.04.019", "author": "MC Hoffman", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Clin Nutr ESPEN", "key": "1432_CR116", "unstructured": "Hoffman MC, Freedman R, Law AJ, Clark AM, Hunter SK. Maternal nutrients and effects of gestational COVID-19 infection on fetal brain development. Clin Nutr ESPEN. 2021;43:1–8.", "volume": "43", "year": "2021" }, { "DOI": "10.1016/j.eurpsy.2017.06.001", "author": "S Andalib", "doi-asserted-by": "crossref", "first-page": "161", "journal-title": "Eur Psychiatry", "key": "1432_CR117", "unstructured": "Andalib S, Emamhadi MR, Yousefzadeh-Chabok S, Shakouri SK, Høilund-Carlsen PF, Vafaee MS, et al. Maternal SSRI exposure increases the risk of autistic offspring: a meta-analysis and systematic review. Eur Psychiatry. 2017;45:161–6.", "volume": "45", "year": "2017" }, { "DOI": "10.1001/jamapediatrics.2017.0124", "author": "A Mezzacappa", "doi-asserted-by": "crossref", "first-page": "555", "journal-title": "JAMA Pediatr", "key": "1432_CR118", "unstructured": "Mezzacappa A, Lasica PA, Gianfagna F, Cazas O, Hardy P, Falissard B, et al. Risk for autism spectrum disorders according to period of prenatal antidepressant exposure: a systematic review and meta-analysis. JAMA Pediatr. 2017;171:555–63.", "volume": "171", "year": "2017" }, { "DOI": "10.1001/jama.2017.3413", "author": "AC Sujan", "doi-asserted-by": "crossref", "first-page": "1553", "journal-title": "JAMA", "key": "1432_CR119", "unstructured": "Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA. 2017;317:1553–62.", "volume": "317", "year": "2017" }, { "DOI": "10.1001/jamapsychiatry.2019.2859", "author": "E Dragioti", "doi-asserted-by": "crossref", "first-page": "1241", "journal-title": "JAMA Psychiatry", "key": "1432_CR120", "unstructured": "Dragioti E, Solmi M, Favaro A, Fusar-Poli P, Dazzan P, Thompson T, et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry. 2019;76:1241–55.", "volume": "76", "year": "2019" }, { "DOI": "10.1176/appi.ajp.2020.18070766", "author": "ML Vega", "doi-asserted-by": "crossref", "first-page": "506", "journal-title": "Am J Psychiatry", "key": "1432_CR121", "unstructured": "Vega ML, Newport GC, Bozhdaraj D, Saltz SB, Nemeroff CB, Newport DJ. Implementation of advanced methods for reproductive pharmacovigilance in autism: a meta-analysis of the effects of prenatal antidepressant exposure. Am J Psychiatry. 2020;177:506–17.", "volume": "177", "year": "2020" }, { "DOI": "10.1016/j.psychres.2021.113912", "author": "LM Tomfohr-Madsen", "doi-asserted-by": "crossref", "first-page": "113912", "journal-title": "Psychiatry Res", "key": "1432_CR122", "unstructured": "Tomfohr-Madsen LM, Racine N, Giesbrecht GF, Lebel C, Madigan S. Depression and anxiety in pregnancy during COVID-19: A rapid review and meta-analysis. Psychiatry Res. 2021;300:113912.", "volume": "300", "year": "2021" }, { "author": "N Kreuzberger", "first-page": "CD013825", "journal-title": "Cochrane Database Syst Rev", "key": "1432_CR123", "unstructured": "Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021;9:CD013825.", "volume": "9", "year": "2021" }, { "DOI": "10.1136/bmj.n2422", "author": "E Mahase", "doi-asserted-by": "crossref", "first-page": "n2422.", "journal-title": "BMJ", "key": "1432_CR124", "unstructured": "Mahase E. Covid-19: molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021;375:n2422.", "volume": "375", "year": "2021" }, { "DOI": "10.1038/d41586-021-02988-4", "doi-asserted-by": "publisher", "key": "1432_CR125", "unstructured": "Sidik SM. Common antidepressant slashes risk of COVID-19 death. Nature. 2021. https://doi.org/10.1038/d41586-021-02988-4." } ], "reference-count": 125, "references-count": 125, "relation": {}, "score": 1, "short-container-title": [ "Mol Psychiatry" ], "short-title": [], "source": "Crossref", "subject": [ "Cellular and Molecular Neuroscience", "Psychiatry and Mental health", "Molecular Biology" ], "subtitle": [], "title": [ "Mechanisms of action of fluvoxamine for COVID-19: a historical review" ], "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }